2008-11-08 13:36:02 -
- BioSphere Medical, Inc. (NASDAQ: BSMD) ("BioSphere") - a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy - announced today that Richard Faleschini, president and chief executive officer, is scheduled to present at the following investment conferences:
--
Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10th at 5:45 p.m. Eastern Time, at the New York Palace Hotel in New York.
-- Stephens Inc. Fall Investment Conference on Tuesday, November 18th at 3:30 p.m. Eastern Time, at the New York Palace Hotel.
Both presentations will also be broadcast live over the Internet via the "Investors" page of the BioSphere Medical Web site at www.biospheremed.com. To listen to the live events, go to the Web site at least 15 minutes early to register, download and install any necessary audio software. Webcasts of both presentations will be available at the Company's Web site for 30 days following each event.
The Rodman & Renshaw 10th Annual Healthcare Conference will feature presentations from more than 400 public and privately held emerging growth healthcare companies presenting data on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. Details regarding the conference can be obtained at www.rodmanandrenshaw.com.
The Stephens Inc. Fall Investment Conference will feature presentations from public and private companies representing numerous industries. Additional details regarding the conference are available at www.stephens.com.
About BioSphere Medical, Inc.
BioSphere Medical, Inc. seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure, as well as in a number of other new and established medical treatments.
Company Contact:
BioSphere Medical, Inc.
Martin Joyce, EVP & CFO, 781-681-7925
www.biospheremed.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
www.lhai.com
